Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

5.72

Margin Of Safety %

Put/Call OI Ratio

1.13

EPS Next Q Diff

-0.08

EPS Last/This Y

0.95

EPS This/Next Y

0.76

Price

156.43

Target Price

157.31

Analyst Recom

1.69

Performance Q

21.99

Relative Volume

0.9

Beta

1.05

Ticker: GKOS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19GKOS143.742.060.839320
2024-12-20GKOS150.972.050.159365
2024-12-23GKOS148.553.101.807289
2024-12-24GKOS151.223.082.447386
2024-12-26GKOS152.653.071.107423
2024-12-27GKOS151.252.990.457536
2024-12-30GKOS149.572.993.787546
2024-12-31GKOS150.071.355.847909
2025-01-02GKOS149.781.363.257948
2025-01-03GKOS151.511.401.258034
2025-01-06GKOS155.341.400.458041
2025-01-07GKOS156.611.421.378054
2025-01-08GKOS158.131.420.128088
2025-01-09GKOS158.121.420.128088
2025-01-10GKOS156.551.420.048160
2025-01-13GKOS151.871.220.428825
2025-01-14GKOS147.881.181.179002
2025-01-15GKOS149.651.170.6712595
2025-01-16GKOS156.551.120.2412491
2025-01-17GKOS156.41.130.1712451
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19GKOS143.7239.771.1-1.83
2024-12-20GKOS150.9339.767.1-1.83
2024-12-23GKOS148.3639.771.6-1.83
2024-12-24GKOS151.2239.769.2-1.83
2024-12-26GKOS152.6739.769.8-1.83
2024-12-27GKOS151.1339.771.2-1.83
2024-12-30GKOS149.5339.771.2-1.83
2024-12-31GKOS150.1839.770.2-1.83
2025-01-02GKOS149.5439.770.7-1.83
2025-01-03GKOS151.6839.769.6-1.83
2025-01-06GKOS155.3039.768.8-1.83
2025-01-07GKOS156.6339.769.9-1.83
2025-01-08GKOS158.1239.769.8-1.83
2025-01-09GKOS158.1239.770.5-1.83
2025-01-10GKOS156.6539.771.1-1.83
2025-01-13GKOS151.9639.772.4-1.83
2025-01-14GKOS147.9739.772.2-1.83
2025-01-15GKOS149.6539.769.7-1.83
2025-01-16GKOS156.5539.767.4-1.83
2025-01-17GKOS156.4339.770.5-1.83
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19GKOS-2.241.535.01
2024-12-20GKOS-2.241.535.01
2024-12-23GKOS-2.131.535.01
2024-12-24GKOS-2.741.535.01
2024-12-26GKOS-2.821.534.84
2024-12-27GKOS-2.871.534.84
2024-12-30GKOS-2.901.554.84
2024-12-31GKOS-2.901.554.84
2025-01-02GKOS-2.861.554.84
2025-01-03GKOS-2.871.554.84
2025-01-06GKOS-2.841.634.84
2025-01-07GKOS-2.841.634.84
2025-01-08GKOS-2.871.634.84
2025-01-09GKOS-2.861.634.84
2025-01-10GKOS-2.751.634.84
2025-01-13GKOS-2.751.625.72
2025-01-14GKOS-2.761.625.72
2025-01-15GKOS-2.761.625.72
2025-01-16GKOS-2.761.625.72
2025-01-17GKOS-2.761.625.72
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.28

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.36

Insider Transactions

-2.76

Institutional Transactions

1.62

Beta

1.05

Average Sales Estimate Current Quarter

100

Average Sales Estimate Next Quarter

106

Fair Value

Quality Score

48

Growth Score

47

Sentiment Score

38

Actual DrawDown %

2.9

Max Drawdown 5-Year %

-64.3

Target Price

157.31

P/E

Forward P/E

PEG

P/S

23.93

P/B

12.89

P/Free Cash Flow

EPS

-2.96

Average EPS Est. Cur. Y​

-1.83

EPS Next Y. (Est.)

-1.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-41.51

Relative Volume

0.9

Return on Equity vs Sector %

-41.5

Return on Equity vs Industry %

-35

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

70.5
Glaukos Corporation
Sector: Healthcare
Industry: Medical Devices
Employees: 907
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
stock quote shares GKOS – Glaukos Corporation Stock Price stock today
news today GKOS – Glaukos Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch GKOS – Glaukos Corporation yahoo finance google finance
stock history GKOS – Glaukos Corporation invest stock market
stock prices GKOS premarket after hours
ticker GKOS fair value insiders trading